Skip to main content
. 2022 May 10;63(7):e68–e73. doi: 10.1111/epi.17269

FIGURE 1.

FIGURE 1

Diagnostic yield of positive molecular diagnoses within and outside of the Behind the Seizure® (BTS) sponsored program. (A) Overall and (B) ceroid lipofuscinosis type 2 (CLN2) disease diagnostic yield among children stratified by age at time of testing and age at seizure onset. Outside of BTS, age at seizure onset was unknown and age at time of testing was used. MDx, molecular diagnosis/diagnoses.